Download Vetter Pharma's whitepaper on Anticipating success: Meeting the inherent challenges of complex drug substances

Realizing the full potential of a novel injectable drug compound is no small task. In the months and years that lead from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can slow development to a halt, often at key stages.

A careful, systematic approach to identifying where and why these roadblocks can occur is fundamental to staying on course. Just as important is a robust, repeatable process design focused on retaining the stability of a compound as it moves through clinical development. The early-stage data captured during this period can play a valuable role in an efficient transition from lab to clinic to market.

We will be gathering inspiring biotech leaders in Asia's biopharma industry together at the 10th BioPharma Asia Convention 2017 , happening in Singapore on 21-23 March . Leading biotech entrepreneurs, biopharma organizations and associations, and big pharma players from both APAC and international will offer you a 360 degree overview of how India is innovating to lead the race to Asia’s biopharma future.

Find out more: http://www.terrapinn.com/exhibition/bio-asia/index.stm

To sign up, contact Sunny Wilson at sunny.wilson@terrapinn.com or +65 6322 2340.